Table 1.
Author, year | Age (years) | iStent generation | iStent number | Follow-up (months) | Number of eyes | Baseline IOP (mmHg) | End point IOP (mmHg) | Number of baseline medications | Number of end point medications | Reduction in IOP (mmHg) | Reduction in number of medications |
---|---|---|---|---|---|---|---|---|---|---|---|
Buznego, 2008 [17] | NR | First | 1 | 18 | 41 | 21.5 ± 6.9 | 16.7 ± 6.9 | 1.6 ± 1.7 | 0.4 ± 1.7 | 4.8 | 1.2 |
Ahmed et al., 2014 [18] | 62.8 ± 12.6 | First | 2 | 18 | 39 | 22.2 ± 2.0 | 11.8 ± 2.1 | 2 ± 0 | 1 ± 0 | 10.4 | 1 ± 0 |
Fea et al., 2014 [19] | 64.5 ± 10.3 | Second | 2 | 12 | 94 | 21.1 ± 1.7 | 13.0 ± 2.3 | 1 ± 0 | 0.09 ± 0.40 | 8.1 ± 2.6 | 0.91 ± 0.40 |
Voskanyan et al., 2014 [20] | 66.4 ± 10.9 | Second | 2 | 12 | 99 | 22.1 ± 3.3 | 15.7 ± 3.7 | 2.21 ± 0.44 | NR | 6.4 | 1.78 ± 0.91 |
Donnenfeld et al., 2015 [21] | 66.7 ± 10.0 | First | 2 | 36 | 39 | 20.6 ± 2.0 | 15.2 ± 2.1 | 1 ± 0 | NR | 5.5 ± 2.7 | NR |
Katz et al., 2015 [22] | 68.1 ± 9.1 | First | 1 | 18 | 38 | 19.8 ± 1.3 | 15.6 ± 1.5 | 1.71 ± 0.61 | 0.111 ± 0.5 | 4.2 | 1.6 |
67.8 ± 9.3 | First | 2 | 18 | 41 | 20.1 ± 1.6 | 13.8 ± 1.3 | 1.76 ± 0.54 | 0.121 ± 0.394 | 6.3 | 1.64 | |
60.9 ± 8.1 | First | 3 | 18 | 40 | 20.4 ± 1.8 | 12.1 ± 1.2 | 1.51 ± 0.69 | 0.079 ± 0.269 | 8.3 | 1.50 | |
Klamann et al., 2015 [23] | 61.67 ± 5.15 | Second | 2 | 6 | 17 (POAG) | 21.19 ± 2.56 | 14.19 ± 1.38 | 2.19 ± 0.91 | 0.88 ± 0.62 | 7.0 | 1.31 |
62.76 ± 4.81 | Second | 2 | 6 | 15 (PEX) | 23.75 ± 3.28 | 15.33 ± 1.07 | 2.33 ± 1.23 | 1.04 ± 0.30 | 8.42 | 1.29 | |
Ferguson et al., 2016 [24] | 80.07 ± 8.54 | First | 1 | 24 | 42 | 20.26 ± 6.00 | 13.62 ± 4.55 | 1.95 ± 1.01 | 1.33 ± 1.22 | 6.64 | 0.62 |
Lindstrom et al., 2016 [25] | 65.3 ± 9.0 | Second | 2 | 18 | 57 | 19.5 ± 1.5 | 14.4 ± 2.1 | 1 ± 0 | 0.02 ± 0.13 | 5.1 | 0.98 |
Vold et al., 2016 [26] | 64.5 ± 11.1 | First | 2 | 36 | 54 | 25.5 ± 2.5 | 14.6 ± 2.4 | 0 ± 0 | 0.21 ± 0.54 | 10.9 | 0.79 |
Berdahl et al., 2017 [27] | 64.7 ± 9.6 | Second | 2 | 18 | 53 | 19.7 ± 1.5 | 12.9 ± 2.1 | 2 ± 0 | 1 ± 0 | 6.8 | 1 ± 0 |
Chang et al., 2017 [28] | 62.8 ± 12.6 | First | 2 | 36 | 39 | 22.4 ± 2.3 | 14.0 ± 2.6 | 2 ± 0 | 1 ± 0 | 8.4 | 1 ± 0 |
Pahlitzsch et al., 2017 [29] | 68.6 ± 16.4 | First | 2 | 6 | 20 | 21.3 | 16.0 | 2.45 | 2.5 | 5.3 | Increase 0.05 |
Shiba et al., 2017 [30] | 64.6 ± 10.7 | First | 2 | 6 | 10 | 22.0 ± 3.0 | 16.9 ± 3.6 | NR | NR | 5.1 | NR |
Katz et al., 2018 [31] | 68.1 ± 9.1 | First | 1 | 42 | 38 | 19.8 ± 1.3 | 15.0 ± 2.8 | 1.71 ± 0.61 | 0.55 ± 0.50 | 4.8 | 1.16 |
68.1 ± 9.1 | First | 2 | 42 | 41 | 20.1 ± 1.6 | 15.7 ± 1.0 | 1.76 ± 0.54 | 0.105 ± 0.307 | 4.4 | 1.66 | |
68.1 ± 9.1 | First | 3 | 42 | 40 | 20.4 ± 1.8 | 14.8 ± 1.3 | 1.53 ± 0.69 | 0.08 ± 0.27 | 5.6 | 1.45 | |
Ahmed et al., 2019 [32] | 66.5 ± 9.5 | First | 2 | 12 | 77 | 19.1 ± 3.6 | 18.1 ± 3.7 | 2.7 ± 0.8 | 1.69 ± 1.37 | 1.0 | 1.01 |
Hengerer et al., 2019 [33] | 71.3 ± 10.5 | Second | 2 | 36 | 44 | 25.3 ± 6.0 | 14.6 ± 2.0 | 2.98 ± 0.88 | 0.55 ± 0.79 | 10.7 | 2.43 |
PEX = pseudoexfoliation glaucoma.